Understanding Carbapenemase Transmission in Carbapenem-Resistant Enterobacter cloacae: Insights from Guangdong Hospitals

Study Background and Research Question

The global rise of carbapenem-resistant Enterobacteriaceae (CRE) represents a significant public health threat, often leaving clinicians with limited therapeutic options for severe Gram-negative bacterial infection research and clinical care. Among CRE, carbapenem-resistant Enterobacter cloacae (CREC) has emerged as a critical pathogen, ranking third in detection rates in China after Klebsiella pneumoniae and Escherichia coli (source: paper). The COVID-19 pandemic has compounded this challenge by increasing antibiotic use and disrupting infection control, potentially accelerating the spread of multidrug-resistant organisms. Despite growing concern, systematic investigations of the molecular characteristics and transmission dynamics of carbapenemase-encoding genes (CEGs) in CREC, particularly during the pandemic, are scarce. This study addresses critical gaps by analyzing 54 CREC isolates from eight teaching hospitals in Guangdong Province, China, collected between December 2022 and June 2024, to delineate the genetic basis and epidemiological patterns of carbapenem resistance.

Key Innovation from the Reference Study

The central innovation of this work lies in its integration of molecular genotyping, mobile genetic element analysis, and conjugation assays to comprehensively map the prevalence, genetic context, and transferability of CEGs in CREC during a period of heightened antimicrobial pressure (source: paper). Unlike prior surveillance studies focused primarily on clinical incidence or resistance phenotypes, this research provides high-resolution data on the horizontal and vertical transmission of specific CEGs, notably blaNDM-1, within and across hospital settings. Furthermore, the study contextualizes these molecular findings within demographic and clinical data, revealing associations between CEG carriage and patient factors such as age, sex, clinical department, and specimen source. This multi-layered approach enables a deeper understanding of factors driving the emergence and persistence of multidrug-resistant CREC in tertiary care environments.

Methods and Experimental Design Insights

A rigorous, multi-method approach was used to characterize the CEG landscape:

• Sample Collection: 54 non-duplicate CREC isolates were obtained from eight geographically distributed teaching hospitals.
• Genetic Analysis: Variable temperature Sodium Dodecyl Sulfate (SDS) plasmid elimination and polymerase chain reaction (PCR) were employed to detect CEGs, including blaNDM-1, blaIMP, and blaKPC-2.
• Broth Microdilution: Antimicrobial susceptibility was assessed, with a focus on resistance to key agents such as imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin.
• Plasmid Conjugation and PCR: To assess the transferability of CEGs, conjugation experiments and follow-up PCR confirmation were performed.
• Mobile Genetic Element Typing: Six types of mobile genetic elements, with ISEcp1 being the most prevalent, were identified.
• Genotyping: ERIC-PCR and NTSYS software facilitated cluster analysis, categorizing isolates into 17 genotypes.

This multifaceted strategy provided an integrated view of both the molecular and epidemiological dimensions of resistance.

Protocol Parameters

• assay | variable temperature SDS plasmid elimination | 46/54 CEG-positive isolates | Used to differentiate chromosomal vs. plasmid localization of carbapenemase genes | paper
• assay | PCR detection of blaNDM-1, blaIMP, blaKPC-2 | sensitivity >95% | Enables precise assignment of CEG presence and context | paper
• assay | Broth microdilution for antimicrobial susceptibility | MIC determination for imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, levofloxacin | Quantifies resistance phenotype and correlates with genotypic data | paper
• assay | Plasmid conjugation | 95.65% success rate for CEG transfer | Assesses horizontal gene transfer potential | paper
• assay | ERIC-PCR genotyping | 17 genotypes identified among 54 isolates | Elucidates clonal diversity and transmission patterns | paper

Core Findings and Why They Matter

The study's core findings underscore the complexity and public health significance of carbapenemase-mediated resistance in CREC:

• CEGs were detected in 85.19% (46/54) of CREC isolates, with blaNDM-1 the most prevalent gene (source: paper).
• blaNDM-1 was found on both plasmids and chromosomes in 33.33% of cases, and exclusively on plasmids in 46.30%—highlighting the versatility and transferability of resistance (source: paper).
• Conjugation experiments demonstrated a high rate (95.65%) of horizontal gene transfer for CEGs, emphasizing the risk of rapid dissemination in hospital environments (source: paper).
• Resistance rates to key antibiotics, including agents used for the treatment of bacterial pneumonia and bronchitis, were significantly higher in CEG-positive strains, particularly for imipenem, ceftazidime/avibactam, and fluoroquinolones (source: paper).
• Mobile genetic elements, especially ISEcp1, were widespread, with some isolates harboring up to four element types simultaneously, further supporting the potential for complex gene transfer events (source: paper).
• High detection rates were observed in elderly patients, men, the respiratory medicine department, and sputum samples, aligning with known clinical risk profiles for Gram-negative infections (source: paper).

These findings confirm that multidrug resistance in CREC is driven by both chromosomal and plasmid-encoded CEGs, and that horizontal gene transfer is a dominant mechanism underpinning their spread.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on the implications of these data:

• The article "Carbapenemase Genes in CREC: Dynamics and Resistance in Guangdong" offers a broader context for the regional epidemiology of CREC, reinforcing the reference study’s findings regarding high CEG prevalence and the importance of infection control.
• "Ceftazidime: Advanced Strategies for Combating β-Lactamase..." explores the role of third-generation cephalosporins like ceftazidime in Gram-negative bacterial infection research, including the challenges posed by β-lactamase resistance mechanisms such as those characterized in the current study.
• Meanwhile, "Ceftazidime: Strategic Insights for Translational Gram-Negative Research" discusses workflow strategies for addressing multidrug resistance, which are directly relevant to the experimental approaches and resistance profiles identified in the Guangdong CREC study.

These articles collectively provide a framework for understanding both the molecular genetics of resistance and practical intervention strategies in translational and clinical research settings.

Limitations and Transferability

While the study offers valuable molecular and epidemiological insights, certain limitations should be recognized:

• The sample size (54 isolates) and geographic scope (eight hospitals in Guangdong) may limit generalizability to other regions or hospital types.
• Temporal coverage is restricted to December 2022–June 2024; ongoing surveillance is warranted to monitor evolving trends.
• Although the study robustly links CEG carriage with resistance phenotypes, it does not experimentally address the impact on clinical outcomes or therapeutic efficacy.

Nevertheless, the detailed analysis of mobile genetic elements and high rates of horizontal transfer suggest the findings are highly relevant for infection prevention strategies and for research focused on the mechanisms of Gram-negative resistance.

Research Support Resources

To support further research into CREC resistance mechanisms, the use of well-characterized antibiotics such as Ceftazidime (SKU B3539) from APExBIO can be considered. As a third-generation cephalosporin with a broad spectrum of activity against Gram-negative bacteria, Ceftazidime is highly resistant to β-lactamase hydrolysis and is suitable for modeling resistance and susceptibility in in vitro and translational workflows (workflow_recommendation). Researchers are advised to follow best practices for storage and solution preparation to ensure experimental reproducibility. For detailed experimental protocols and recent insights into β-lactamase resistance, internal resources such as "Ceftazidime: Advanced Strategies for Combating β-Lactamase..." provide further guidance.